SHL Medical to introduce new device for cardiometabolic therapies
First look at a new solution for cardiometabolic drug delivery
![[.png] A pen injector device against a blue background. The device is Quanta, SHL Medical’s latest device offering that supports cardiometabolic therapies.](https://cdn.bfldr.com/DTG6CG68/at/qrh7tzctv97gmknff7rkz7s/shl-medical-introduce-new-device-cardiometabolic-therapies-banner.png?width=480&auto=webp&format=webp)
SHL Medical’s expanding device portfolio is about to welcome a new addition as we gear up to debut Quanta™, a new pen injector platform, marking an important step forward in our cardiometabolic offering.
Cardiometabolic therapies have been among the fastest-growing segments in pharma, driving demands for device innovation and scalability. Within this landscape, multi-fixed-dose devices are emerging as an important alternative, especially in cost-sensitive markets.
Quanta is our answer to pharma’s need for new device solutions in the cardiometabolic space. Developed to address growing cost pressures and the economic implications of large patient populations, Quanta reflects our continued commitment to delivering device solutions that stay ahead of evolving market needs.
See it first in Paris
Quanta will make its global debut at Pharmapack Europe 2026, taking place January 21-22 at Paris Expo, Porte de Versailles. Be among the first to experience the device at our Booth #4D22, and join our product spotlight tour or workshop presentation to learn more about its features.
Stay tuned for more details. In the meantime, get the first look of Quanta.